To include your compound in the COVID-19 Resource Center, submit it here.

Athersys, Healios expanding MultiStem deal

Athersys Inc. (NASDAQ:ATHX) and Healios K.K. (Tokyo:4593) entered into a letter of intent (LOI) to expand Healios' license to develop MultiStem products to include treatment of acute respiratory distress syndrome (ARDS)

Read the full 317 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE